CHEBI:50750 - EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
ChEBI ID CHEBI:50750
Definition A topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
Stars This entity has been manually annotated by the ChEBI Team.
Secondary ChEBI IDs CHEBI:132229, CHEBI:50234
ChEBI Ontology
Outgoing EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750) is a topoisomerase inhibitor (CHEBI:70727)
Incoming (R)-temafloxacin (CHEBI:77794) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
(S)-temafloxacin (CHEBI:77795) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
4'-epidoxorubicin (CHEBI:47898) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
4,4'-propane-1,3-diyldipiperazine-2,6-dione (CHEBI:50231) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
aclacinomycin A (CHEBI:74619) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
aclacinomycin A zwitterion (CHEBI:77980) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
amsacrine (CHEBI:2687) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
betulinic acid (CHEBI:3087) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
celastrol (CHEBI:63959) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
ciprofloxacin (CHEBI:100241) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
ciprofloxacin dihydrochloride (CHEBI:59938) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
ciprofloxacin hydrochloride (anhydrous) (CHEBI:310388) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
ciprofloxacin hydrochloride hydrate (CHEBI:59936) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
dihydrobetulinic acid (CHEBI:65485) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
ellagic acid (CHEBI:4775) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
fisetin (CHEBI:42567) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
fleroxacin (CHEBI:31810) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
flumequine (CHEBI:85267) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
gatifloxacin (CHEBI:5280) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
genistein (CHEBI:28088) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
kaempferol 3-O-α-L-arabinopyranosyl-7-O-α-L-rhamnopyranoside (CHEBI:68878) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
kaempferol 3-O-β-D-apiofuranosyl-7-O-α-L-rhamnopyranoside (CHEBI:68884) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
kaempferol 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside (CHEBI:68882) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
kaempferol 3-O-(5-O-acetyl-α-D-apiofuranosyl)-7-O-α-L-rhamnopyranoside (CHEBI:68877) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
lucanthone (CHEBI:51052) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
maleimide (CHEBI:16072) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
manoalide (CHEBI:66666) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
methyl brevifolincarboxylate (CHEBI:66711) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
nepalensinol D (CHEBI:66616) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
nepalensinol E (CHEBI:66617) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
nepalensinol F (CHEBI:66618) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
novobiocin (CHEBI:28368) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
procyanidin B4 (CHEBI:27589) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
temafloxacin (CHEBI:77788) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
teniposide (CHEBI:75988) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
TOP-53 (CHEBI:134547) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
wedelolactone (CHEBI:10037) has role EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor (CHEBI:50750)
Synonyms Sources
DNA gyrase inhibitor ChEBI
DNA gyrase inhibitors ChEBI
DNA topoisomerase (ATP-hydrolysing) (EC 5.99.1.3) inhibitor ChEBI
DNA topoisomerase (ATP-hydrolysing) (EC 5.99.1.3) inhibitors ChEBI
DNA topoisomerase (ATP-hydrolysing) inhibitor ChEBI
DNA topoisomerase (ATP-hydrolysing) inhibitors ChEBI
DNA topoisomerase II inhibitor ChEBI
DNA topoisomerase II inhibitors ChEBI
EC 5.99.1.3 (DNA topoisomerase (ATP-hydrolysing)) inhibitor ChEBI
EC 5.99.1.3 (DNA topoisomerase (ATP-hydrolysing)) inhibitors ChEBI
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitors ChEBI
EC 5.99.1.3 inhibitor ChEBI
EC 5.99.1.3 inhibitors ChEBI
inhibitor of type II topoisomerase ChEBI
inhibitors of type II topoisomerase ChEBI
topoisomerase II inhibitor ChEBI
topoisomerase II inhibitors ChEBI
topoisomerase-II inhibitor ChEBI
topoisomerase-II inhibitors ChEBI
type II DNA topoisomerase inhibitor ChEBI
type II DNA topoisomerase inhibitors ChEBI
Last Modified
17 February 2017